Products
Online Inquiry
Recilisib
Cat. No.:
OB0225WX-1531
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Recilisib is a unique radioprotective small molecule that functions by stimulating the intracellular signaling activities of both PI3K and AKT.
Synonym:
Ex-RAD; ON 01210; 334969-03-8; (E)-4-(2-((4-Chlorobenzyl)sulfonyl)vinyl)benzoic acid; 4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoic acid; 4-((1E)-2-(((4-chlorophenyl)methyl)sulfonyl)ethenyl)benzoic acid; Benzoic acid, 4-((1E)-2-(((4-chlorophenyl)methyl)sulfonyl)ethenyl)-; Exrad; Recilisibum; 4-((E)-2-((4-chlorophenyl)methylsulfonyl)ethenyl)benzoic acid; 4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]benzoic acid
CAS No.:
334969-03-8
Compound CID:
9884220
Formula:
C16H13ClO4S
Formula Weight:
336.79
Specification
Relative Density:
1.423 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Recilisib is applied in radiation biology research to examine its potential as a radioprotective agent and its ability to modulate intracellular signaling pathways following ionizing radiation exposure.
Library Information
Target:
PI3K; Akt
Receptor:
PI3K; Akt
Pathways:
Cytoskeletal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-20
Plate Location:
f6
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 148.46 mM
